Apellis Q1 FY26 swings to net income of $18.66 million; revenue rises 61% to $268.3 million

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.

APLS

0.00
  • Apellis Pharmaceuticals swung to net income of USD 18.66 million as revenue climbed 61% to USD 268.3 million.
  • Net product revenue rose 28% to USD 192.01 million, led by SYFOVRE at USD 150.7 million and EMPAVELI at USD 41.3 million.
  • Licensing and other revenue more than tripled to USD 76.29 million, including USD 25 million tied to Royalty Agreement and USD 30 million in regulatory development milestones.
  • Operating income totaled USD 26.47 million as research and development expense fell 11% to USD 76.96 million.
  • Biogen launched a tender offer on April 14 to acquire all shares for USD 41 per share in cash plus a contingent value right worth up to USD 4, with closing expected mid-second quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001492422-26-000108), on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.